logo
Share SHARE
FONT-SIZE Plus   Neg

Roche, PTC Sign Deal To Advance Treatment For Spinal Muscular Atrophy

Roche Holding AG (RHHBY.PK), PTC Therapeutics, Inc. and the SMA Foundation, announced a licensing agreement for PTC's Spinal Muscular Atrophy, or SMA, programme. SMA is a genetic neuromuscular disorder that causes muscle weakness.

As per the terms of the agreement, Roche gains an exclusive worldwide license to PTC's SMA programme, which includes three compounds currently in preclinical development, as well as potential back-up compounds. PTC receives $30 million as an upfront payment, up to $460 million upon successful completion of certain development and commercialization milestones and up to double-digit royalties on commercial sales. PTC noted that development will be overseen by a joint steering committee comprised of members from Roche, PTC and the SMA Foundation.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The month of May saw the FDA greenlight 5 new drugs, including 1 new molecular entity, and surprisingly turn down 1 drug candidate, whose approval was considered a no-brainer by some experts. Lab equipment maker Thermo Fisher Scientific Inc. has agreed to acquire electron microscope maker FEI Co. for about $4.2 billion in cash, the two companies said Friday. Thermo Fisher noted that FEI's electron microscopy platform will complement its own mass spectrometry systems to accelerate advancements in structural biology. While reporting a wider loss for the first quarter, Sears Holdings Corp. said it has decided to "aggressively evaluate" all potential alternatives for its top brands - Kenmore, Craftsman and DieHard or KCD, and the Sears Home Services or SHS businesses. Sears has retained Citigroup Global Markets and LionTree Advisors to assist in its efforts.
comments powered by Disqus
Follow RTT